Late-phase trials of targeted therapies for elevated lipoprotein(a) are nearing completion, with the first readouts expected later this year.

A single lipoprotein(a) screening in a person’s lifetime could significantly reduce their risk for heart disease-related morbidity and mortality, yet this opportunity is often…

Late-phase trials of targeted therapies for elevated lipoprotein(a) are nearing completion, with the first readouts expected later this year.